Homogeneous, structurally defined heparin-oligosaccharides with low anticoagulant activity inhibit the generation of the amplification pathway C3 convertase in vitro - PubMed (original) (raw)
. 1988 Sep 15;263(26):13090-6.
Affiliations
- PMID: 3417651
Free article
Homogeneous, structurally defined heparin-oligosaccharides with low anticoagulant activity inhibit the generation of the amplification pathway C3 convertase in vitro
R J Linhardt et al. J Biol Chem. 1988.
Free article
Abstract
This paper demonstrates that heparin-oligosaccharides with low anticoagulant activity have a high capacity to inhibit activation of the amplification pathway of complement in vitro. We prepared heparin-oligosaccharides by partial depolymerization of heparin using purified flavobacterial heparinase. The resulting oligosaccharide mixture was then fractionated using strong anion exchange-high pressure liquid chromatography to produce individual oligosaccharide components of this mixture, with degree of polymerization ranging from 2 to 16. These heparin-oligosaccharides were examined for both their anticoagulant activity and capacity to inhibit activation of the amplification pathway of complement. Although there was little difference among commercial heparins, a correlation between molecular weight and activity to inhibit convertase generation was clearly established for heparin-oligosaccharides between degree of polymerization 2 through 16. Heparin-oligosaccharides of degree of polymerization 10-16 (Mr 3888-5320) demonstrated up to 54% of heparin's activity on a molar basis (and up to 163% of heparin's activity on a weight basis) in inhibiting the amplification pathway of complement in vitro while showing almost no anticoagulant activity. These studies, for the first time, completely separate heparin's ability to inhibit complement activation from its anticoagulant activity.
Similar articles
- Synthetic oligosaccharides as heparin-mimetics displaying anticoagulant properties.
Avci FY, Karst NA, Linhardt RJ. Avci FY, et al. Curr Pharm Des. 2003;9(28):2323-35. doi: 10.2174/1381612033453929. Curr Pharm Des. 2003. PMID: 14529394 Review. - Structural determinants of the capacity of heparin to inhibit the formation of the human amplification C3 convertase.
Kazatchkine MD, Fearon DT, Metcalfe DD, Rosenberg RD, Austen KF. Kazatchkine MD, et al. J Clin Invest. 1981 Jan;67(1):223-8. doi: 10.1172/JCI110017. J Clin Invest. 1981. PMID: 6778897 Free PMC article. - Rational design of anticoagulant drugs using oligosaccharide chemistry.
El Hadri A, Petitou M. El Hadri A, et al. Chimia (Aarau). 2011;65(1-2):14-7. doi: 10.2533/chimia.2011.14. Chimia (Aarau). 2011. PMID: 21469438 Review.
Cited by
- Heparin, Low Molecular Weight Heparin, and Non-Anticoagulant Derivatives for the Treatment of Inflammatory Lung Disease.
Shute JK. Shute JK. Pharmaceuticals (Basel). 2023 Apr 13;16(4):584. doi: 10.3390/ph16040584. Pharmaceuticals (Basel). 2023. PMID: 37111341 Free PMC article. Review. - Coagulopathy and Fibrinolytic Pathophysiology in COVID-19 and SARS-CoV-2 Vaccination.
Yamada S, Asakura H. Yamada S, et al. Int J Mol Sci. 2022 Mar 19;23(6):3338. doi: 10.3390/ijms23063338. Int J Mol Sci. 2022. PMID: 35328761 Free PMC article. Review. - Heparin - Messias or Verschlimmbesserung?
Swan D, Carrier M, Lisman T, Thachil J. Swan D, et al. J Thromb Haemost. 2021 Oct;19(10):2373-2382. doi: 10.1111/jth.15464. Epub 2021 Jul 29. J Thromb Haemost. 2021. PMID: 34272818 Free PMC article. Review. - Glycosaminoglycan Compositional Analysis of Relevant Tissues in Zika Virus Pathogenesis and in Vitro Evaluation of Heparin as an Antiviral against Zika Virus Infection.
Kim SY, Koetzner CA, Payne AF, Nierode GJ, Yu Y, Wang R, Barr E, Dordick JS, Kramer LD, Zhang F, Linhardt RJ. Kim SY, et al. Biochemistry. 2019 Feb 26;58(8):1155-1166. doi: 10.1021/acs.biochem.8b01267. Epub 2019 Feb 13. Biochemistry. 2019. PMID: 30698412 Free PMC article. - Pathogenesis and Inhibition of Flaviviruses from a Carbohydrate Perspective.
Kim SY, Li B, Linhardt RJ. Kim SY, et al. Pharmaceuticals (Basel). 2017 May 4;10(2):44. doi: 10.3390/ph10020044. Pharmaceuticals (Basel). 2017. PMID: 28471403 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous